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Abstract: 
 
Background: Aging of the HIV positive (HIV+) cohort has introduced the challenges of 
managing comorbidities and syndromes traditionally associated with older adults. Frailty, a 
state of vulnerability to stressor events that is associated with adverse functional outcomes 
has been demonstrated in HIV+ individuals, with varying prevalence across the studies. 
 
Objectives: To describe the prevalence and predictors of frailty in individuals living with HIV 
using systematic review methodology.  
 
Methods: We searched Medline, CINAHL, EMBASE, PsychInfo and PubMed for original 
observational studies with populations inclusive of HIV+ individuals in which frailty was 
assessed using the frailty phenotype or a variant thereof. Studies were examined for frailty 
prevalence and key predictors of the syndrome in those with HIV.    
 
Results: 13 of 322 citations were included for full review. All demonstrated the presence of 
frailty in HIV with prevalence ranging from 5% to 28.6% depending on population studied. 
HIV was a risk factor for frailty when compared to those without HIV. Key predictors of 
frailty included increasing age, presence of comorbidity, an AIDS diagnosis and low current 
CD4+ cell count.  
 
Conclusions: HIV appears to be an independent risk factor for frailty, with frailty occurring in 
HIV+ individuals at rates comparable to older HIV negative cohorts. Accurate description of 
the problem is hampered by heterogeneity in study populations and frailty assessment 
measures. Future longitudinal work with standardised methodology is needed to accurately 
describe prevalence and confirm the key predictors.   
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Introduction:  
 
Improved survival with modern combined anti-retroviral therapy (cART) alongside increased 
later life acquisition of HIV is driving an increase in the age of the HIV-positive (HIV+) cohort. 
HIV in the older individual presents a number of challenges, including an excess in 
comorbidities not traditionally associated with HIV infection (1) including falls (2), functional 
impairment (3) and frailty (4), which feature more commonly in older HIV-negative (HIV-) 
‘geriatric’ populations. Whether HIV itself or treatment toxicities cause premature or 
accelerated aging is subject to ongoing debate (5,6) and is considered research priority(7).  
 
With an ever increasing number of older adults engaged in HIV care, services will need to 
adapt to meet their complex needs. In general chronological age may not be the best 
predictor of prognosis or individual need (8) and a more useful model for risk stratification 
may be the presence or absence of frailty. Frailty describes a state of increased vulnerability 
to stressor events resulting from declines in multiple physiological systems. When present, 
frailty is associated with adverse outcomes including falls, hospital admission and death(9–
11). The difficulty in using frailty as a concept is the lack of consensus definition, particularly 
regarding how it should be measured(12). The most widely used model in both HIV+ and 
HIV- populations is the frailty phenotype (FP) (13) characterised by Fried et al(9). The FP 
comprises five criteria; weight loss, exhaustion, low physical activity, weak grip strength and 
slow walking speed; with frailty defined by the presence of three or more criterion. Those 
with one or two are classed as pre-frail and none as robust(9). 
 
There is heterogeneity in HIV frailty research with different authors using various measures 
and definitions of frailty making it difficult to fully quantify the burden of frailty in the 
context of HIV. We therefore aim to conduct a systematic review of the original literature 
pertaining to frailty prevalence and predictors in individuals with HIV, using the FP as a 




Search Strategy  
We aimed to identify observational studies assessing frailty status in individuals with HIV.  
We therefore conducted a systematic electronic search using the following Healthcare 
databases; Medline, CINAHL, EMBASE, PsychInfo and PubMed. They were searched from 
January 2000 to April 2014, using database appropriate MeSH terms alongside “HIV”, 
“Human Immunodeficiency Virus”, “Acquired Immunodeficiency Syndrome” combined with 
“frail*”, “reduced functional reserve”, “functional impairment”, “reduced physiological 
reserve”, and “physiological vulnerability”. Broad ‘function’ terms were used to capture 
studies where frailty was part of wider functional assessment. International HIV/AIDS 
conference abstracts and major HIV and Gerontology journals were also searched. 
Additionally, reference lists of relevant review articles and articles reviewed at full-text 
stage were screened by hand to identify potentially missing studies.  
 
Eligibility Criteria  
In article selection we applied the following inclusion criteria: (i) original observational 
research presented; (ii) frailty defined using the Fried FP, or modified variant thereof, to 
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allow standardisation. We therefore excluded studies published before its description in 
2001. (iii) Inclusion of data on HIV+ adults; (iv) frailty prevalence for HIV+ individuals should 
be stated, easily calculable or obtainable from authors. Studies not meeting the above 
criteria were excluded. Though language was not an exclusion criterion or limit set during 
database searches, all citations found were written in English.  
 
Study selection  
Selection for full text review was independently conducted by two reviewers (TL and FC), by 
applying eligibility criteria to the title and abstract. Articles deemed relevant, or where 
further clarification of eligibility was required, were retrieved for full text review. Authors 
were contacted where points of clarification were needed(14–17). The reviewers 
independently assessed selected full text articles and after discussion and consensus review 
where needed (by MF) a list of studies for inclusion was finalised.  
 
Quality Assessment  
We evaluated study quality, with respect to bias using the Newcastle-Ottawa Scale 
(NOS)(18). The NOS is a method of quality assessment for non-randomised studies with 
scales available for different observational methodologies, which were applied in this case 
depending on study type. Broadly the NOS criteria evaluate quality in three domains: 
Selection; Comparability and Outcome, awarding a designated number of stars to each 
study in each domain depending on whether quality markers are met. We adapted the scale 
for cross-sectional studies by reducing the weight allocated to validation of exposure (HIV) 
and outcome (frailty), to be awarded one rather than two points, making weighting 
comparable to that awarded for cohort/case-control scales, preventing artificially high 
quality scoring of cross-sectional studies. Given the importance of statistical analysis, scoring 
for an appropriate approach was substituted into schemes for cohort and case-control study 
design types.  
 
Data Extraction  
A data extraction form was designed and independently applied to each study by TL and FC. 
Data was extracted on study design, population characteristics, frailty definition and frailty 
prevalence (for HIV+ and HIV- where control groups included) along with significant frailty 
predictors. Data extracted by each reviewer were compared for consistency and any 
disagreements resolved by consensus or use of a third reviewer (MF).  
 
Statistical Analysis  
We planned to conduct a meta-analysis of frailty prevalence to generate a summary 
prevalence with corresponding 95% confidence interval. Comprehensive Meta-analysis 
software (Englewood, USA) was used. A random effect meta-analysis on the included 
studies presenting cross-sectional data was performed(14,19–24), producing summary 
prevalence of 8.6% (95% CI 6.5 to 11.3). However heterogeneity was high with an I-squared 
score of 77.63, which did not reduce to below 75 with sensitivity analysis when additional 
factors were considered including country of origin (US versus non-US), ethnicity (Caucasian 
versus black predominance), age (average age above/below 50) or ART use (all versus 
some). Given that variability in prevalence is largely due to heterogeneity across the studies 
we have chosen not to present the findings as a meta-analysis further. In order to assess 
potential publication bias we created a funnel plot (figure 1), which owing to the limited 
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number of studies in our review cannot provide conclusive evidence. However, from the 
observed funnel plot the spread of studies is more or less symmetrical, suggesting an 




Search results and study selection 
Literature review found 322 citations, 275 from database searches and 47 from index 
searching of bibliographies, journals and conference proceedings. Of these 103 were 
duplications and a further 178 excluded after title/abstract review due to non-relevance. 41 
were selected for full text review, with a further 28 exclusions due to duplicated 
presentation of data (6), lack of frailty assessment (12), frailty not defined by FP (4) or 
absence of primary data (6). 13 studies met full inclusion-criteria. Selection and exclusions 
shown in figure 2.  
 
Study characteristics  
Of the 13 studies selected five were of cohort design (two prospective, three retrospective) 
(15,17,25–27), with four presenting data from the Multicentre AIDS cohort study (MACS) 
(17,25–27). One study used case-control design(22) and seven were cross-sectional (19–
21,23,24,28) (one nested within a prospective cohort) (14). 11 were presented in full article 
format and two as conference abstracts. Studies were largely urban community or 
University clinic based, with only one from a resource-poor setting(22). Studies varied in size 
from 41 to 2150. Studies were mainly US based (11/13) with the two remaining studies from 
Mexico and South Africa. All utilised a frailty assessment based on FP criteria, with the three 
retrospective cohort studies utilising a frailty related phenotype (FRP) comprised of four 
rather than five criteria as grip strength data was lacking (25–27). One study measured 
phenotypic criteria differently to other studies (28). General study characteristics and 
description of frailty parameters are shown in table 1.  
 
Quality 
Quality as assessed using design-specific NOS showed that out of a maximum available nine 
points there was a range from three to eight, with lower quality scores assigned to 
conference abstracts as shown in table 2.  
 
Frailty prevalence  
Prevalence was measured in two ways across the studies. Where cross-sectional data was 
presented the prevalence was provided for individuals and ranged from 5% in the Mexican 
study (23) to 28.6% in the MACS cohort (17). In the included MACS articles frailty was 
assessed on multiple occasions allowing for prevalence to be calculated using total number 
of individuals as the denominator (based on at least one visit with frailty), ranging 13.9 to 
28.6% and using total person visits as the denominator, which resulted in lower prevalence 
(5.4 -12%) (17,26). Across the MACS timeline, prevalence of frailty in terms of person-visits 
decreased from 7.6% in 1994-95 (pre-cART era) to 4.5% in 2000-2005 (post-cART era) with 
increases in median age from 41 to 48 and proportion of those on treatment from 42.3% to 
80.2%. In the most recent evaluation, from 2007-2011 (established cART era) where frailty 
was assessed prospectively with the addition of grip strength, prevalence had risen to 12% 
of person visits or 28.6% of individuals with at least one frailty visit, along with further 
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increases in median age to 53.8 and in proportion receiving cART from 80.2% to 84.2%. 
Piggott (15) presents data from the ALIVE cohort including HIV+/- individuals with past or 
present intravenous drug use (IDU), in which FP was present in 12.3% of all participants and 
12.4% of person visits. Dividing participants by HIV status, 14.6% of HIV+ and 11.3% HIV- 
were frail (data provided by author).  
 
Predictors of frailty 
HIV status 
Five studies included HIV- controls. The MACS cohort examined frailty pre-cART introduction 
(25) where the prevalence of FRP in HIV- participants was 1.5%. In this study, for years 1994-
1996, the OR adjusted for age, ethnicity and education for expressing FRP in HIV+ individuals 
compared to HIV- was 10.97 (95% CI 6.37-18.88) when all person-visits were analysed. This 
reduced, but remained significant at 4.49 (95% CI 1.98-10.09) when weight loss, which had 
high association with HIV pre-cART, was removed as a FRP criterion. With established cART  
Althoff (for MACS) demonstrates a significantly higher frailty prevalence in HIV+ compared 
to HIV- men (12% vs. 9% p=0.002) (17). Further support for an association with HIV status is 
provided in the ALIVE cohort where HIV was associated with a 66% increased likelihood of 
frailty (aOR 1.66; 95% CI 1.24-2.21) (15) and in Pathai’s study where the adjusted OR of 
frailty in those with HIV was 2.14 (95% CI; 1.16-3.92) (22).   
 
Age 
In the pre-cART MACS, a 10-year increase in age was associated with a significantly 
increased risk of frailty with OR 1.61 (95% CI 1.21-2.15), which reduced but remained 
significant when AIDS was excluded (OR 1.53, 1.11-2.11) (25). This persisted in the cART era 
(1996-2005) with a 10-year age increase associated with an OR 1.52 (95% CI 1.24-1.87) (26). 
In later MACS data from 2007-2011, the proportion of visits where frailty was demonstrated 
increased with increasing age (17). Age was significantly associated with frailty in two 
additional studies (15,21). In Pathai’s South African study, increasing age was a significant 
predictor in HIV+ women but not men (OR 2.50, CI 1.35–4.58), in a predominantly female 
HIV+ cohort (73.1%) (22). Ianas showed no association with age and frailty after controlling 
for CD4 count, but increasing age was significantly associated with lower CD4 count, which 
did predict frailty (20). 
 
Socio-demographic factors   
Studies varied in socio-demographic factors presented. In early MACS analysis pre-1996 
(25), college education was associated with frailty, however post-1996 the converse is seen 
with lower educational attainment associated with (OR 1.73 95% CI 1.19-2.50) (26) and 
conversion to frailty (17). This association between frailty and lower educational 
achievement is supported by Onen but not others (21). Ethnicity (non-Hispanic black) was 
only associated with frailty in the MACS cohort post-1996 (26,17). Unemployment and low 
annual income were significantly associated with frailty in two studies (19,21) but not 
reported elsewhere.  
 
Co-morbid conditions 
Compared to robust individuals with HIV, those with frailty had significantly more 
comorbidities (15,17,19,21). The most consistently replicated of which include psychiatric 
disease, particularly moderate to severe depression (19,21,26,17), cognitive impairment 
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(21), chronic kidney disease (21,17), diabetes (17) and low BMI (21,22). Hepatitis C co-
infection was only associated with frailty in one study and was restricted to those aged 50 
and over (20).  
 
HIV factors 
CD4+ cell count 
Reduced CD4+ count was the most consistently reported HIV factor associated with frailty, 
with current CD4+ (14,15,19,22,25,26,17) more predictive than nadir count, which only 
showed significant association in one study (21). In MACS, median CD4+ count increased 
over the duration of the study with corresponding drop in frailty prevalence overall. 
However, the risk of frailty increased as CD4+ fell, with adjusted OR for FRP (with 95% CI) of 
2.80 (1.97-3.98), 1.98 (1.57-2.50) and 1.36 (1.22-1.50) for CD4+ counts of 100, 200 and 350 
cells/mm3 respectively (26). This CD4+ relationship was also observed within one cross-
sectional study, with frailty prevalence 43.5%, 19.2% and 7.8% for CD4+ of <200, 200-350, 
>350 cells/mm3 respectively (20). A high CD4+ count was protective of frailty in one study, 
with CD4+ >750 cells/mm3 associated with OR 0.66 (95% CI 0.57-076)(26). Importantly, 
CD4+ count remained a strong predictor of frailty even in those with viral suppression, and 
when AIDS and comorbidities such as TB and hepatitis C were controlled for (22,26). 
 
Viral load   
Viral load (VL) is not as strongly associated with frailty as CD4+ count, with positive 
association observed only in pre-cART MACS where those with VL >50,000 copies/ml had 
2.91 the odds of FRP (95% CI 1.08-7.85) than those without (25). Frailty remained more 
common in those with VL>50,000 in the post-cART era but not significantly so after 
adjusting for CD4 count (26). Other studies report no significant association with peak or 




Where the relationship between AIDS (not including CD4+ <200 cells/mm3) and frailty was 
examined, all but one study (19) showed the risk of frailty to be higher in those with AIDS. In 
MACS, risk was reduced following the introduction of cART, with OR for FRP with AIDS 9.89 
(95% CI, 4.70–20.80) and 3.34 (95% CI, 2.24-4.94) pre- and post-cART respectively (26). Such 
association was less evident in a study of women, where the elevated risk of frailty was only 
seen in univariate (OR 1.55; 1.03-2.34) and not multivariate analysis and when AIDS was 
excluded frailty prevalence in those with HIV was 7% compared to 8% in negative controls 
(14). Lastly those with AIDS had an increased likelihood of becoming frail over those without 




Our systematic review found multiple studies which all demonstrated the occurrence of 
frailty in adults living with HIV. Frailty prevalence, ranged from 5.0 to 28.6% depending on 
the cohort studied. Frailty in these studies was associated with increasing age, but was 
present at younger ages not traditionally associated with frailty, which is mainly seen as a 
syndrome of ‘old age’.  When compared to HIV-negative individuals, HIV increased the 
likelihood of developing frailty and in those with HIV, increasing age, presence of 
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comorbidity, an AIDS diagnosis and low current, and possibly nadir CD4+ cell-count were 
predictors of frailty. 
 
To our knowledge this is the first evaluation of frailty in HIV using systematic review 
methodology. The strengths of this study include our comprehensive search strategy 
encompassing multiple electronic databases alongside searches of conference proceedings 
and target journals in an attempt to ensure that all of the published literature was captured. 
Additionally our focus on frailty assessment based upon the Fried FP allowed for a degree of 
standardisation across the studies. Although heterogeneity was still considerable it would 
have been worsened by inclusion of alternative frailty assessment methods. In spite of 
recent international attempts there is still no consensus definition of frailty (12,29) but the 
FP was the most commonly used tool in population-based studies (13).  
 
To contextualise the frailty prevalence in those with HIV, studies in HIV negative populations 
where the FP has been employed include the US Cardiovascular Health Study of community-
dwelling adults aged ≥65  where prevalence was 6.9% (9); The Study of Health, Aging and 
Retirement in Europe which investigated a younger cohort (50-64) demonstrating 
prevalence of 4.1%, which increased to 17.1% in those ≥65 (30) and lastly a 2012 systematic 
review including 15 studies of community-dwelling adults aged ≥65 (n=44,894) showed a 
prevalence of 9.9% (31). Therefore the prevalence seen in the broadly younger HIV+ 
population, with highest median age of 57, is comparable to cohorts of community-dwelling 
adults aged ≥65.  
 
There are some limitations to this systematic review. Firstly, despite a thorough search 
strategy it is always possible that some articles have been missed. This would be important 
if these missing studies contradicted the findings presented here; however given the global 
finding of frailty occurrence and broadly consistent associated factors we feel the impact 
would be small. Secondly there was a large amount of heterogeneity across the studies both 
in terms of the populations studied and the interpretation of the FP making comparisons 
difficult. Thirdly transitions between frailty states was not evaluable in the cross-sectional 
studies and where measured in longitudinal studies showed movement in and out of frailty, 
which makes defining its occurrence difficult. Lastly some of the data presented comes from 
the era before effective ART, so may not reflect the currently largely well-treated cohort, 
who may have a different ageing trajectory to those diagnosed before its availability.  
 
To expand, the heterogeneity of the populations studied limits our ability to make clear 
comparisons between all of the studies. The longitudinal cohorts included restricted study 
populations by solely including MSMs, the IDU experienced or women. Additionally there is 
a geographical bias as most studies originate from the US and the two non-US studies 
represented the lowest and second highest frailty prevalence. This may in part be due to a 
female predominance in the latter compared to the majority male samples elsewhere, as 
globally frailty appears more prevalent in women than men (10,32).  However the study by 
Terzian (14) had 100% women but lower frailty prevalence than that of Pathai (22) 
supporting a need to explore geographical differences in relation to frailty in HIV and the 
many potential confounders such as nutrition, late versus early diagnosis, HIV duration and 
ART experience. Additionally the majority of studies are based on convenience over random 
sampling strategies making it difficult to tease out the role of selection bias and 
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confounding. Most recruited through HIV-clinics and those attending clinics may represent 
the less-well end of service user spectrum and bias frailty towards overestimation or 
conversely, the fitter end of the cohort may be more able to attend or be more proactive 
about their own health leading to underestimation.   
 
With regards the interpretation of the FP, the vast majority used either a frailty related 
phenotype based on retrospective data or a modified frailty phenotype, all of which, 
including the original phenotype have not been validated in younger HIV+ cohorts which 
may affect the accuracy of frailty diagnosis with potential for misclassification. In MACS 
particularly, frailty may have been underestimated when four rather than five criteria were 
used, as a trend of reducing frailty prevalence was reversed with the addition of grip 
strength in 2005 (17). However despite this lack of validation, where the predictive ability of 
the phenotype in terms of adverse outcomes has been examined this appears consistent 
with that of traditional elderly cohorts (15,21,27). Additionally using population based cut-
offs for phenotypic criteria has been shown to correlate well to original methodology (33). 
There is however a general criticism of the FP method in that it represents a one-
dimensional approach to frailty that focuses too heavily on physical characteristics whilst 
neglecting broader cognitive, functional and social parameters (34).  
 
This review has identified some important predictors of frailty in individuals with HIV. Most 
notably is the association with low current CD4+ count, which reflects advanced HIV and 
stresses the importance of proactive testing to avoid late diagnosis where CD4+ count is by 
definition lower, the magnitude of CD4 reconstitution on ART is less, and the risk of frailty 
appears highest. This finding is important as immune dysfunction and the possible 
association with uncontrolled inflammation has been implicated in the pathophysiology of 
frailty outside of HIV (11).  
 
This review highlights the key issue of frailty in individuals with HIV, which appears to have 
prevalence comparable to HIV-negative individuals aged over 65. We have shown that 
important predictors include increasing age, advanced immunosuppression and the 
presence of comorbidities. We have stressed the limitations in current work and 
recommend an ongoing need for further research in this area in the form of well-designed 
longitudinal cohort studies in mixed populations that reflects the current cohort ageing in 
the presence of HIV. Future work should ideally be conducted across the lifespan to allow 
incident frailty and frailty dynamics, particularly pre-frail state, to be assessed along with 
predictors of transitions such as age, immune thresholds and comorbidity burdens. Though 
challenging, well-chosen controls will help to unpick the contribution of HIV over other 
disease and socio-demographic factors to frailty. Lastly longitudinal work will permit us to 
investigate whether frailty in individuals with HIV is associated with the same adverse 
outcomes seen in HIV- older adults, which if present should promote clinical and research 
activity into prevention and/or reversal of frailty.  
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Table 1: Characteristics of included studies 
First author, 
year (Country) 








% (% pv)b 
Outcome measure Frailty criteria  
Althoff, 2013 
(USA)(17) 
Cohort Multicentre AIDS Cohort 
(MACS) 
MSMs >18 years old +/- HIV 
Urban community  









Frail if ≥3/5 criteria  
Weakness (grip strengthc) 
Slowness (4m timed walkc)  
Self-reported weight loss 
Self-reported exhaustiond  
Low physical activitye 
Desquilbet, 2007 
(USA)(25) 
Cohort  MACS  
HIV- cohort  
Apr 1994-Nov 2004 
HIV+ cohort  
Apr 1994-Jan 1996 
39  
(median) 
100 2150  245 13.9 
(7.2) 
Retrospective FRP 
Frail if ≥3/4 criteria  
Self-reported slownessf 
Self-reported  
Self-reported exhaustiond  
Low physical activitye 
Desquilbet, 2009 
(USA)(26) 
Cohort  MACS  
HIV+ cohort  
April 1994-April 2005 
45 
(median) 
100 1046  106 - 
(5.4)  
Retrospective FRP. 
Frail if ≥3/4 criteria  
Self-reported slownessf 
Self-reported  
Self-reported exhaustiond  
Low physical activitye 
Desquilbet, 2011 
(USA)(27) 
Cohort  MACS 




100 596 596 13.9 Retrospective FRP. 
Frail if ≥3/4 criteria  
Self-reported slownessf 
Self-reported  
Self-reported exhaustiond  





HIV+ aged 45-65 on ART 
University Hospital clinic 
January 2009-January 2010 
50.8  
(median) 
85 359 359 7.5 Prospective modified 
FP. 
Low function (frail) if 
≥3/5 criteria  
Weakness (grip strengthg) 
Slowness (4.5m timed-walkh)  
Self-reported weight loss 
Self-reported exhaustioni 





Convenience sample.  
HIV+ ≥18 years +/- ART 




74 100 100 19.0 Prospective modified 
FP.  
Frail if ≥3/5 criteria  
Weakness (grip strengthg) 
Slowness (4.5m timed-walkh)  
Self-reported weight loss 
Self-reported exhaustioni 




Onen, 2009 Cross- Convenience sample 41.7 71 445 445 9.0 Prospective modified Weakness (grip strengthg) 
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(USA)(21) sectional  University Hospital clinic 
HIV+ ≥18 years +/- ART 
June-December 2008 
(mean)  FP.  
Frail if ≥3/5 criteria  
Slowness (4.5m timed-walkh)  
Documented weight loss 
Self-reported exhaustioni 






Unselected sample >30 years 
HIV+ +/-ART  
Community treatment centre 





27 504 248 19.4 Prospective modified 
FP.  
Frail if ≥3/5 criteria  
Weakness (grip strengthg) 
Slowness (4.5m timed-walkh)  
Documented weight loss 
Self-reported exhaustioni 
Low physical activitye 
Piggott, 2013 
(USA)(15) 
Cohort  AIDS linked to Intravenous 
experience (ALIVE).  
History IVDU +/- HIV 
Community-based cohort  
From July 2005 
48.7  
(median) 
63 1230 357 14.6 Prospective modified 
FP.  
Frail if ≥3/5 criteria  
Weakness (grip strengthg) 
Slowness (4.5m timed-walkh)  
Documented weight loss 
Self-reported exhaustioni 








University Hospital clinic  




71 41 41 17.1 Prospective modified 
FP.  
Frail if ≥3/5 criteria  
Weakness (grip >1 SD below mean) 
Slowness (Timed Gait Test >11 secs) 
Self-reported weight loss 
Exhaustion (Fatigue Severity Scale 
score >36) 





Nested within Women’s 
Interagency HIV Study  
Urban, community cohort of 




100 1781 1206 9.0 Prospective modified 
FP.  
Frail if ≥3/5 criteria  
Weakness (grip strength) 
Slowness (4m walk time)  
Self-reported weight loss 
Self-reported exhaustioni 
Low physical activitye. 






Community Study  




80 116 116 5.0 Prospective FP ‘Fried phenotype’  










94 142 142 8.5 Prospective FP  
 
‘Fried phenotype’  
Individual criteria not specified. 
a- Total study population  
b- frailty prevalence based on person-visits 
c- lowest 20% for activity 
d- “yes” to “during the past 4 weeks, as a result of your physical health, have you had difficulty 
h- Predefined cut-offs based on gender and height 
i- Response of 3-4 days per week or most of the time “everything I did was an effort” or “I just could 
not get going’ on the CES-D (Center for Epidemiological Studies Depression) scale. 
ART- anti-retroviral therapy  
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performing your work or other activities? 
e- “yes, limited a lot” to the question “Does your health now limit you in vigorous activities?” 
f- “yes, limited a lot” to “Does your health now limit you walking several blocks?” 
g- Predefined cut-offs based on gender and BMI 
 
FP- frailty phenotype 
FRP- frailty related phenotype  
IVDU- intravenous drug use 
MSM- men who have sex with men 
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Table 2: Newcastle-Ottawa scale quality evaluation by design type 
 
First author, year  Selection Comparability Outcome Total 
Cohort design  
Althoff, 2013 (17) 3 2 3 8 
Desquilbet, 2007 (25) 2 2 3 7 
Desquilbet, 2009 (26) 2 2 3 7 
Desquilbet, 2011 (27) 3 2 2 7 
Piggott, 2013 (35) 2 2 2 6 
Case-control 
Pathai, 2012 (22) 2 2 3 7 
Cross-sectional  
Erlandson, 2012 (19) 2 2 3 7 
Ianas, 2012 (20) 2 2 3 7 
Onen, 2009 (21) 3 0 3 6 
Sandkovsky, 2013 (28) 3 1 2 6 
Terzian, 2009 (14) 2 2 3 7 
Abstracts- ( cross-sectional design)  
Davilla, 2013 (23) 2 0 2 4 
Greene, 2014 (24) 2 0 2 4 
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Logit event rate 
Figure 1: A funnel-plot to assess publication bias of included 
studies (utilizing random effects model) 
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Original Search Medline, CINAHL, EMBASE, 
PsychInfo, Pubmed, Conference Proceedings and 
selected specialist ageing and HIV journals 
322 Citations 
 
Title and abstract review 
281 excluded 
103 Duplicates 
178 Non-relevant  







6- Not primary 
research  
13 citations selected for inclusion 
 5 cohort studies  
1 case-control study 
5 cross-sectional studies 
2 conference abstracts  
